APRE Share Price Performance
US$1.49
-1.14 (-43.32%)
Price US$1.49
Share PriceUS$1.49
Aprea Therapeutics, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 3 Fair Values set on narratives written by author
APRE Community Narratives
There are no narratives available yet.
Recent APRE News & Updates
Aprea Therapeutics, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -2.38
- Gross Margin
- -1,041.57%
- Net Profit Margin
- -1,646.84%
- Debt/Equity Ratio
- 0%
Aprea Therapeutics, Inc. Competitors
Snowflake Analysis
About APRE
- Founded
- n/a
- Employees
- 8
- CEO
- WebsiteView website
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers; and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
U.S. Market Performance
- 7 Days: 1.1%
- 3 Months: 8.9%
- 1 Year: 18.9%
- Year to Date: 15.1%
The market is up 1.1% over the last week, with the Information Technology sector leading the way, up 1.9%. In the last year, the market has climbed 19%. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›